Authors
PhD in Public Health, Deputy CEO for Academic Affairs at Nazareth & Galilee College
Master’s student in Clinical Psychology from An-Najah National University, Nablus, Palestine
Abstract
The use of nanoparticles as biomarkers for monitoring disease activity in colitis has gained significant attention in recent years due to their high sensitivity and specificity in detecting inflammatory processes. Recent studies have demonstrated that nanoparticles, including gold nanoparticles (AuNPs), quantum dots (QDs), and magnetic nanoparticles (MNPs), can enhance early detection and monitoring of inflammatory bowel diseases (IBD), such as ulcerative colitis (UC) and Crohn’s disease (CD) (Smith et al., 2021; Patel et al., 2022). These nanoparticle-based approaches offer a non-invasive alternative to traditional diagnostic methods like colonoscopy and blood tests, with improved accuracy and lower patient burden (Zhang & Wang, 2020). Statistical comparisons indicate that AuNP-based biomarkers achieve a detection accuracy of over 90% in UC and CD patients, significantly outperforming conventional polymerase chain reaction (PCR) blood tests and imaging techniques (Jones et al., 2023). This article critically evaluates the efficacy, limitations, and clinical applications of nanoparticle technologies in colitis diagnostics, emphasizing their potential for revolutionizing disease monitoring and timely therapeutic interventions.